Non-segmented negative sense RNA viruses as vectors for vaccine development

Current Science

Volumn 98, Issue 3, 2010, Pages 379-391

  Suryanarayana, V V S ^a   Chattopadhyay, Dhrubajyothi ^b   Shaila, M S ^c  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF CALCUTTA   (India)

^c INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Chandipura virus; Chimeric viruses; Nonsegmented negative sense RNA viruses; Vaccine vectors; Virus replication

Indexed keywords

CHANDIPURA VIRUS; RHABDOVIRIDAE; RNA VIRUSES;

EID: 77953354449     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (112)

1. Smith, G. L., Mackett, M. and Moss, B., Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature, 1983, 302, 490-495.
2. Abraham, G. and Banerjee, A. K., Sequential transcription of the genes of vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA, 1976, 73, 1504-1508.
3. Alexander Bukreyev, Mario H. Skiadopoulos, Brian R. Murphy and Peter L. Collins, Nonsegmented negative-strand viruses as vaccine vectors. J. Virol., 2006, 10293-10306.
4. Ball, L. A. and White, C. N., Order of transcription of genes of vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA, 1976, 73, 442-446.
5. Banerjee, A. K., The transcription complex of vesicular stomatitis virus. Cell, 1987b, 48, 363-364.
6. Banerjee, A. K., Transcription and replication of rhabdoviruses. Microbiol. Rev., 1987a, 51, 66-87.
7. Banerjee, A. K., Moyer, S. and Rhodes, D., Studies on the in vitro adenylation of RNA by vesicular stomatitis virus. Virology, 1974, 61, 547-558.
8. Basak, S. et al., Leader RNA binding ability of Chandipura virus P protein is regulated by its phosphorylation status: a possible role in genome transcription-replication switch. Virology, 2003, 307, 372-385.
9. Chattopadhyay, D., Raha, T. and Chattopadhyay, D., Single serine phosphorylation within the acidic domain of Chandipura virus P protein regulates the transcription in vitro. Virology, 1997, 239, 11-19.
10. Barik, S. and Banerjee, A. K., Sequential phosphorylation of the phosphoprotein of vesicular stomatitis virus by cellular and viral protein kinases is essential for transcription activation. J. Virol., 1992b, 66, 1109-1118.
11. Keene, J. D., Thornton, B. J. and Emerson, S. U., Sequencespecific contacts between the RNA polymerase of vesicular stomatitis virus and the leader RNA gene. Proc. Natl. Acad. Sci. USA, 1981, 78, 6191-6195.
12. Rose, J. K., Complete intergenic and flanking gene sequences from the genome of vesicular stomatitis virus. Cell, 1980, 19, 415-421.
13. Mebatsion and Conzelmann, K. K., Infectious rabies viruses from cloned cDNA. EMBO J., 1994, 13, 4195-4203.
14. Buonocore, L., Blight, K. J., Rice, C. M. and Rose, J. K., Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol., 2002, 76, 6865-6872.
15. Durbin, A. P., Hall, S. L., Siew, J. W., Whitehead, S. S., Collins, P. L. and Murphy, B. R., Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology, 1997, 235, 323-332.
16. Garcin, D., Pelet, T., Calain, P., Roux, L., Curran, J. and Kolakofsky, D., A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J., 1995, 14, 6087-6094.
17. Kato, A., Sakai, Y., Shioda, T., Kondo, T., Nakanishi, M. and Nagai, Y., Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells, 1996, 1, 569-579.
18. Lawson, N. D., Stillman, E. A., Whitt, M. A. and Rose, J. K., Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA, 1995, 92, 4477-4481.
19. Nakaya, T. et al., Recombinant Newcastle disease virus as a vaccine vector. J. Virol., 2001, 75, 11868-11873.
20. Newman, J. T., Surman, S. R., Riggs, J. M., Hansen, C. T., Collins, P. L., Murphy, B. R. and Skiadopoulos, M. H., Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wildtype recombinant HPIV1 produced by reverse genetics. Virus Genes, 2002, 24, 77-92.
21. Peeters, B. P., de Leeuw, O. S., Koch, G. and Gielkens, A. L., Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol., 1999, 73, 5001-5009.
22. Radecke, F. et al., Rescue of measles viruses from cloned DNA. EMBO J., 1995, 14, 5773-5784.
23. MacDonald, G. H. and Johnston, R. E., Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol., 2000, 74, 914-922.
24. Spann, K. M., Collins, P. L. and Teng, M. N., Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J. Virol., 2003, 77, 11201-11211.
25. Conzelmann, K. K., Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses. J. Virol., 2005, 79, 5241-5248.
26. Garcia-Sastre, A., Identification and characterization of viral antagonists of type I interferon in negative-strand RNA viruses. Curr. Top. Microbiol. Immunol., 2004, 283, 249-280.
27. Durbin, A. P., McAuliffe, J. M., Collins, P. L. and Murphy, B. R., Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology, 1999, 261, 319-330.
28. Teng, M. N., Whitehead, S. S., Bermingham, A., St Claire, M., Elkins, W. R., Murphy, B. R. and Collins, P. L., Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol., 2000, 74, 9317-9321.
29. +-T-cell memory in mice challenged with unrelated pathogens. J. Virol., 2003, 77, 7756-7763.
30. Collins, P. L., Hill, M. G., Camargo, E., Grosfeld, H., Chanock, R. M. and Murphy, B. R., Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA, 1995, 92, 11563-11567.
31. Enterlein, S., Volchkov, V., Weik, M., Kolesnikova, L., Volchkova, V., Klenk, H. D. and Muhlberger, E., Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J. Virol., 2006, 80, 1038-1043.
32. Volchkov, V. E., Volchkova, V. A., Muhlberger, E., Kolesnikova, L. V., Weik, M., Dolnik, O. and Klenk, H. D., Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science, 2001, 291, 1965-1969.
33. Wyatt, L. S., Moss, B. and Rozenblatt, S., Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology, 1995, 210, 202-205.
34. Buchholz, U. J., Finke, S. and Conzelmann, K. K., Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol., 1999, 73, 251-259.
35. Witko, S. E. et al., An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhabdoviruses from a cell line suitable for vaccine development. J. Virol. Methods, 2006, 135, 91-101.
36. Bukreyev, A. et al., Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol., 2005, 79, 13275-13284.
37. Rose, J. K. and Whitt, M. A., Rhabdoviridae: the viruses and their replication. In Fields Virology (eds Knipe, D. M. et al.), Lippincott-Raven Publishers, Philadelphia, PA, 2001, vol. 1, 4th edn, pp. 1221-1244.
38. Flanagan, E. B., Zamparo, J. M., Ball, L. A., Rodriguez, L. L. and Wertz, G. W., Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J. Virol., 2001, 75, 6107-6114.
39. Skiadopoulos, M. H. et al., Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol., 1999, 73, 1374-1381.
40. Skiadopoulos, M. H., Tao, T., Surman, S. R., Collins, P. L. and Murphy, B. R., Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the liveattenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine, 1999, 18, 503-510.
41. Bartlett, E. J., Amaro-Carambot, E., Surman, S. R., Newman, J. T., Collins, P. L., Murphy, B. R. and Skiadopoulos, M. H., Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine, 2005, 23, 4631-4646.
42. McAuliffe, J. M., Surman, S. R., Newman, J. T., Riggs, J. M., Collins, P. L., Murphy, B. R. and Skiadopoulos, M. H., Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J. Virol., 2004, 78, 2029-2036.
43. Nelson, C. B., Pomeroy, B. S., Schrall, K., Park, W. E. and Lindeman, R. J., An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am. J. Public Health, 1952, 42, 672-678.
44. Bermingham, A. and Collins, P. L., The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl. Acad. Sci. USA, 1999, 96, 11259.
45. Durbin, A. P., McAuliffe, J. M., Collins, P. L. and Murphy, B. R., Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology, 1999, 261, 319-330.
46. McGettigan, J. P., Pomerantz, R. J., Siler, C. A., McKenna, P. M., Foley, H. D., Dietzschold, B. and Schnell, M. J., Secondgeneration rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 Gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol., 2003, 77, 237-244.
47. Publicover, J., Ramsburg, E. and Rose, J. K., Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J. Virol., 2004, 78, 9317-9324.
48. Roberts, A., Buonocore, L., Price, R., Forman, J. and Rose, J. K., Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol., 1999, 73, 3723-3732.
49. Schnell, M. J., Buonocore, L., Boritz, E., Ghosh, H. P., Chernish, R. and Rose, J. K., Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J., 1998, 17, 1289-1296.
50. Pham, Q. N., Biacchesi, S., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L. and Buchholz, U. J., Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J. Virol., 2005, 79, 15114-15122.
51. Garbutt, M. et al., Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol., 2004, 78, 5458-5465.
52. Geisbert, T. W. et al., Development of a new vaccine for the prevention of Lassa fever. PLoS Med., 2005, 2, e183.
53. Mar Perez et al., Generation and characterization of a recombinant vesicular stomatitis virus expressing the glycoprotein of Borna disease virus. J. Virol., 2007, 81, 5527-5536.
54. Jones, S. M. et al., Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med., 2005, 11, 786-790.
55. Kahn, J. S., Roberts, A., Weibel, C., Buonocore, L. and Rose, J. K., Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol., 2001, 75, 11079-11087.
56. Techaarpornkul, S., Collins, P. L. and Peeples, M. E., Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology, 2002, 294, 296-304.
57. Haller, A. A., Miller, T., Mitiku, M. and Coelingh, K., Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J. Virol., 2000, 74, 11626-11635.
58. Pennathur, S. et al., Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys. J. Gen. Virol., 2003, 84, 3253-3261.
59. Schmidt, A. C. et al., Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J. Virol., 2000, 74, 8922-8929.
60. Tao, T., Skiadopoulos, M. H., Davoodi, F., Riggs, J. M., Collins, P. L. and Murphy, B. R., Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J. Virol., 2000, 74, 6448-6458.
61. Schmidt, A. C., McAuliffe, J. M., Murphy, B. R. and Collins, P. L., Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol., 2001, 75(10), 4594-4603.
62. Schmidt, A. C., Wenzke, D. R., McAuliffe, J. M., St. Claire, M., Elkins, W. R., Murphy, B. R. and Collins, P. L., Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host rangeattenuated bovine parainfluenza virus type 3 vector backbone. J. Virol., 2002, 76, 1089-1099.
63. Tang, R. S. et al., A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine, 2005, 23, 1657-1667.
64. Hanson, R. P., Newcastle Disease, Iowa State University Press, Ames, Iowa, 1978, 7th edn.
65. Lippmann, O., Human conjunctivitis due to the Newcastle-disease virus of fowls. Am. J. Ophthalmol., 1952, 35, 1021-1028.
66. Nelson, C. B., Pomeroy, B. S., Schrall, K., Park, W. E. and Lindeman, R. J., An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am. J. Public Health, 1952, 42, 672-678.
67. Martinez-Sobrido, L. et al., Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol., 2006, 80, 1130-1139.
68. Nakaya, Y., Nakaya, T., Park, M. S., Cros, J., Imanishi, J., Palese, P. and Garcia-Sastre, A., Induction of cellular immune responses to simian immunodeficiency virus Gag by two recombinant negative-strand RNA virus vectors. J. Virol., 2004, 78, 9366-9375.
69. Huang, Z., Elankumaran, S., Yunus, A. S. and Samal, S. K., A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J. Virol., 2004, 78, 10054-10063.
70. Park, M. S., Steel, J., Garcia-Sastre, A., Swayne, D. and Palese, P., Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. USA, 2006, 103, 8203-8208.
71. Veits, J. et al., Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. USA, 2006, 103, 8197-8202.
72. Ritchie, B., Harrison, G. and Harrison, L., Avian Medicine: Principles and Application, Wingers Publishing, Lake Worth, Fla, 1993.
73. Letchworth, G. J., Rodriguez, L. L. and Del Cbarrera, J., Vesicular stomatitis. Vet. J., 1999, 157, 239-260.
74. Forger III, J. M., Bronson, R. T., Huang, A. S. and Reiss, C. S., Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system. J. Virol., 1991, 65, 4950-4958.
75. Reiss, C. S., Plakhov, I. V. and Komatsu, T., Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann. NY Acad. Sci., 1998, 855, 751-761.
76. Schlereth, B., Buonocore, L., Tietz, A., ter Meulen, V., Rose, J. K. and Niewiesk, S., Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J. Gen. Virol., 2003, 84, 2145-2151.
77. Fellowes, O. N., Dimopoullos, G. T. and Callis, J. J., Isolation of vesicular stomatitis virus from an infected laboratory worker. Am. J. Vet. Res., 1955, 16, 623-626.
78. Hanson, R. P., Rasmussen Jr, A. F., Brandly, C. A. and Brown, J. W., Human infection with the virus of vesicular stomatitis. J. Lab. Clin. Med., 1950, 36, 754-758.
79. Johnson, K. M., Vogel, J. E. and Peralta, P. H., Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am. J. Trop. Med. Hyg., 1966, 15, 244-246.
80. Quiroz, E., Moreno, N., Peralta, P. H. and Tesh, R. B., A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am. J. Trop. Med. Hyg., 1988, 39, 312-314.
81. Rose, N. F. et al., An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell, 2001, 106, 539-549.
82. Rose, N. F., Roberts, A., Buonocore, L. and Rose, J. K., Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol., 2000, 74, 10903-10910.
83. Egan, M. A. et al., Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res. Hum. Retrovir., 2004, 20, 989-1004.
84. Reuter, J. D. et al., Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J. Virol., 2002, 76, 8900-8909.
85. Kapadia, S. U., Rose, J. K., Lamirande, E., Vogel, L., Subbarao, K. and Roberts, A., Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology, 2005, 340, 174-182.
86. Roberts, A. et al., Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol., 1998, 72, 4704-4711.
87. Roberts, A., Reuter, J. D., Wilson, J. H., Baldwin, S. and Rose, J. K., Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J. Virol., 2004, 78, 3196-3199.
88. Buonocore, L., Blight, K. J., Rice, C. M. and Rose, J. K., Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol., 2002, 76, 6865-6872.
89. Haglund, K., Leiner, I., Kerksiek, K., Buonocore, L., Pamer, E. and Rose, J. K., High-level primary CD8+ T-cell response to human immunodeficiency virus type 1 Gag and Env generated by vaccination with recombinant vesicular stomatitis viruses. J. Virol., 2002, 76, 2730-2738.
90. Schnell, M. J., Buonocore, L., Kretzschmar, E., Johnson, E. and Rose, J. K., Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA, 1996, 93, 11359-11365.
91. Coulon, P., Ternaux, J. P., Flamand, A. and Tuffereau, C., An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro. J. Virol., 1998, 72, 273-278.
92. Mebatsion, T., Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein. J. Virol., 2001, 75, 11496-11502.
93. Yan, X., Mohankumar, P. S., Dietzschold, B., Schnell, M. J. and Fu, Z. F., The rabies virus glycoprotein determines the distribution of different rabies virus strains in the brain. J. Neurovirol., 2002, 8, 345-352.
94. Faber, M., Lamirande, E. W., Roberts, A., Rice, A. B., Koprowski, H., Dietzschold, B. and Schnell, M. J., A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoVneutralizing antibodies. J. Gen. Virol., 2005, 86, 1435-1440.
95. McGettigan, J. P., Foley, H. D., Belyakov, I. M., Berzofsky, J. A., Pomerantz, R. J. and Schnell, M. J., Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J. Virol., 2001, 75, 4430-4434.
96. McGettigan, J. P., Sarma, S., Orenstein, J. M., Pomerantz, R. J. and Schnell, M. J., Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replicationcompetent rhabdovirus-based vaccine vector. J. Virol., 2001, 75, 8724-8732.
97. Schnell, M. J., Foley, H. D., Siler, C. A., McGettigan, J. P., Dietzschold, B. and Pomerantz, R. J., Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc. Natl. Acad. Sci. USA, 2000, 97, 3544-3549.
98. Tan, G. S., McKenna, P. M., Koser, M. L., McLinden, R., Kim, J. H., McGettigan, J. P. and Schnell, M. J., Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology, 2005, 331, 82-93.
99. Hurwitz, J. L., Soike, K. F., Sangster, M. Y., Portner, A., Sealy, R. E., Dawson, D. H. and Coleclough, C., Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine, 1997, 15, 533-540.
100. Skiadopoulos, M. H. et al., Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology, 2002, 297, 153-160.
101. Slobod, K. S. et al., Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine, 2004, 22, 3182-3186.
102. Takimoto, T. et al., Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J. Virol., 2004, 78, 6043-6047.
103. Matano, T. et al., Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med., 2004, 199, 1709-1718.
104. Kato, M. et al., Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine, 2005, 23, 3166-3173.
105. Nolan, S. M., Surman, S. R., Amaro-Carambot, E., Collins, P. L., Murphy, B. R. and Skiadopoulos, M. H., Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine, 2005, 23, 4765-4799.
106. Durbin, A. P., Skiadopoulos, M. H., McAuliffe, J. M., Riggs, J. M., Surman, S. R., Collins, P. L. and Murphy, B. R., Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J. Virol., 2000, 74, 6821-6831.
107. Skiadopoulos, M. H., Surman, S. R., Riggs, J. M., Collins, P. L. and Murphy, B. R., A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J. Virol., 2001, 75, 10498-10504.
108. Tang, R. S. et al., Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J. Virol., 2003, 77, 10819-10828.
109. Bukreyev, A. et al., Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet, 2004, 363, 2122-2127.
110. Bukreyev, A. et al., A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethaldose Ebola virus challenge. J. Virol., 2006, 80, 2267-2279.
111. Zuniga, A. et al., Attenuated measles virus as a vaccine vector. Vaccine, 2007, 25, 2974-2983.
112. Lorin, C. et al., A single infection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralising antibodies and cellular immune responses to HIV. J. Virol., 2004, 78, 146-157.